In this special edition, Dr. Novickij et al. discussed the significance of the shape of electric pulses for membrane permeabilization and its potential applications (https://www.frontiersin.org/articles/10.3389/fonc.2022.958128/full ). Advances in the pulsed power technology can provide a wide range of PEFs with pulse durations from picosecond to millisecond, electric field strengths up to several hundred KV/cm, frequencies up to GHz and varied waveforms. Focusing on the commonly used square waveforms, the authors described the physical features, biological effects, potential mechanisms, advantages, and engineering challenges of several square waveforms including unipolar square wave, bipolar square wave, CANCAN (cancellation of bipolar cancellation) and asymmetric pulses, respectively. Beside the pulse waveform determining pulse duration and electric field amplitude, the authors also discussed the effects of frequency or pulse repetition rate, which is more influential in terms of shorter pulses (<100 µs). In general, cell membrane permeabilization is the foundation of current PEF-based cancer therapies such as ECT, GET, IRE, etc. Contrarily, ultrashort (nanosecond and picosecond) PEFs can affect intracellular structures/organelles whereas leave cell membrane unchanged [1]. Another unique feature of ultrashort (picosecond) PEFs is the feasibility of non-invasive delivery by antenna. NPS has been demonstrated to effectively treat cancers in numerous animal models [2][3][4][5][6] and clinical trials [7,8]. Currently, there are engineering challenges for picosecond PEFs to treat cancer. Nevertheless, We believe the engineering obstacles will be resolved eventually and this noninvasive ultrashort PEF technology will have broad medical applications including cancer therapy [9], deep brain stimulation [10], etc.ECT is the most broadly used PEF-based cancer therapy approved in many countries in contrast to other PEF-based therapies such as IRE, GET, calcium electroporation, NPS, which are currently at various phases in clinical trials. This is also reflected in this special edition. There are four research reports studying the medical applications of ECT. By the analysis of data in the InspECT (International Network for Sharing Practice on ECT) registry, Dr. Bertino, et al. reported the application of ECT to treat 162 cases of cutaneous squamous cell carcinoma (cSCC) (https://www.frontiersin.org/articles/10.3389/fonc.2022.951662/full ). Noticeably, majority of patients having undergone one or more than one prior therapy still obtained an overall response rate of 83% with complete response rate of 62% and partial response rate of 21%. Further analysis demonstrates intravenous drug administration is significantly better than intratumoral administration. Tumor with small sizes and ECT as primary therapy also have better clinical outcomes. As the authors pointed out that this study is not a clinical trial but the analysis of real-world heterogeneous patients with ECT adopted to treat cSCC. Therefore, some conclusions, such as whether intravenous drug administration is better than intratumoral administration, which appears to contradict with other studies, should be further investigated in well-designed clinical trials.The most common cancers treated with ECT are surface malignancies [11] including cSCC, basal cell carcinoma, Karposi's sarcoma, melanoma, skin metastatic tumors, etc. Due to the high effectiveness of local tumor clearance and favorable safety features in these superficial tumors, advanced or enhanced ECT technologies have been developed to treat tumors located in deep tissues/organs. Dr. Trotovsek et al. reported laparoscopic ECT to treat two cases of unresectable hepatocellular carcinoma (HCC) which are unsuitable with cutaneous ECT or other ablation methods (https://www.frontiersin.org/articles/10.3389/fonc.2022.996269/full ). With advances in the electrode designs and accommodated into laparoscopy, endoscopy and other minimal invasive diagnostic/therapeutic systems [12], we can envision ECT will be one therapeutic choice for many other solid tumors regardless of histological types and physical locations. The research article entitled "Combining super selective catheterization and electrochemotherapy: A new technological approach to the treatment of high-flow head and neck vascular malformations" is an example that a technological advance can expand the ECT application to some difficult clinical situations, in this case, high-flow vascular malformations with comorbidities (https://www.frontiersin.org/articles/10.3389/fonc.2022.1025270/full ). Though these two reports are not a standard clinical trial, they demonstrated that a well-trained team could take advantage of ECT to manage complex needs for cancer treatment or tissue ablation while other available therapies face a great challenge. In terms of clinical management of ECT for cancer therapy, anesthesia is part of management plan. In a prospective clinical study, Dr. Benedik et al. assessed the tolerability, safety and potential advantages of two anesthetic techniques: general anesthesia and continuously intravenous sedation (https://www.frontiersin.org/articles/10.3389/fonc.2022.1011721/full ). They found both anesthetic methods achieved similar outcomes in terms of numeric pain score, subjective satisfaction and adverse effect. Continuous intravenous sedation showed some benefits including reduced anesthetic quantity (Propofol) and a faster recovery, which is particularly helpful to patients with comorbidity who might deteriorate with long duration of anesthesia.GET is currently in phase II trials for melanoma and triple negative breast cancer (clinicaltrials.gov) after initially encouraging results from first Phase I human trial [13], which indicates GET is a safe and effective PEF technology for clinical application. Dr. Hollevoet et al. reported a large animal (sheep) study on the dosing and pharmacokinetics of GET with DNA coding antibody (https://www.frontiersin.org/articles/10.3389/fonc.2022.1017612/full ). Their study validates the level of targeted proteins can be tuned by the DNA dose as previous reported by Dr. Heller's group [14,15]. It also indicates a long-term (> one year) protein expression reaching a therapeutic level can be achieved by intramuscular GET if no anti-drug-antibody (ADA) response were induced. In this sheep study ADA response was observed only in one out of 18 or 5.6% of animals, which is similar to [16] or lower than [17] some reported ADA rates for antibody protein therapy in human trials. Antibody therapy has been widely utilized to treat many types of diseases including cancer, infectious diseases, chronic inflammatory disorders, etc. Major limitations include high cost and repetitive administrations. One time GET can generate and maintain a long-term therapeutic level of antibody, which will not significantly reduce the cost but also avoid repetitive protein administrations. Therefore, GET with DNA coding therapeutic antibody has great potential in the cancer therapy and chronic diseases where antibody is one therapeutic choice.We have to emphasize that research in PEF-based technologies and their oncological applications is at the rising phase. Substantial animal studies and clinical trials suggest PEF technologies such as ECT, IRE, GET and NPS, can be highly effective at treating local tumors in a minimally invasive manner with few and manageable side effects. Due to the high efficiency and favorable safety feature, these PEF-based therapies have advantages to treat patients who cannot tolerate with current standard of cares, such as chemotherapy, radical surgery and radiotherapy. One trend for the applications of PEF-based technologies is to improve clinical outcomes by developing effective combination therapies with other cancer treatments. Furthermore, more and more data showed that PEF therapies in certain conditions/models may not only result in local tumor regression but also induce systemic immune responses, which have a distant effect (abscopal tumor regression) and long-term memory (prevention against recurrence). Since the first clinical trial of ECT has been approved to treat tumors [18], three decades have passed. There are many breakthroughs and much progress in terms of PEFbased technologies and applications, yet this research field is still wide open and there are still many questions and challenges. We encourage more oncologists, basic and translational scientists to explore uses of these technologies and become dedicated to these promising technologies for better and more effective cancer control.
6 Authors
- AK
Aljosa Krt
Department of Otorhinolaryngology, Izola General Hospital, Slovenia
- MC
Maja Cemazar
Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia
- DL
Dimitrij Lovric
Department of Radiology, University Medical Centre Ljubljana, Slovenia
- GS
Gregor Sersa
Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia
- CJ
Crt Jamsek
Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Slovenia
- AG
Ales Groselj
Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Slovenia
3,912 views
19 citations
6 Authors
- JB
Janez Benedik
Department of Anesthesiology and Perioperative Intensive Care Medicine, University Medical Centre Ljubljana, Slovenia
- BO
Barbara Ogorevc
Department of Anesthesiology and Perioperative Intensive Care Medicine, University Medical Centre Ljubljana, Slovenia
- SK
Simona Kranjc Brezar
Faculty of Medicine, University of Ljubljana, Slovenia
- MC
Maja Cemazar
Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia
- GS
Gregor Sersa
Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia
- AG
Ales Groselj
Faculty of Medicine, University of Ljubljana, Slovenia
3,164 views
7 citations
5 Authors
- BT
Blaz Trotovsek
Department of Abdominal Surgery, University Medical Center Ljubljana, Slovenia
- BH
Benjamin Hadzialjevic
Department of Abdominal Surgery, University Medical Center Ljubljana, Slovenia
- MC
Maja Cemazar
Department of Experimental Oncology, Institute of Oncology, Slovenia
- GS
Gregor Sersa
Department of Experimental Oncology, Institute of Oncology, Slovenia
- MD
Mihajlo Djokic
Department of Abdominal Surgery, University Medical Center Ljubljana, Slovenia
2,316 views
8 citations
26 Authors
- GB
Giulia Bertino
Department of Otolaryngology Head Neck Surgery, University of Pavia, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Foundation, Italy
- AG
Ales Groselj
Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Slovenia
- LG
Luca G. Campana
Department of Surgery, The Christie National Health Service (NHS) Foundation Trust, United Kingdom
- CK
Christian Kunte
Department of Dermatosurgery and Dermatology, Artemed Fachklinik Munich, Germany
- HS
Hadrian Schepler
Department of Dermatology, University Medical Center, Johannes Gutenberg University, Germany
- JG
Julie Gehl
Center for Experimental Drug and Gene Electrotransfer (CEDGE), Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Denmark
- TM
Tobian Muir
Department of Reconstructive Plastic Surgery, James Cook University Hospital, United Kingdom
- JA
James A. P. Clover
Department of Plastic Surgery, Cork University Hospital, Ireland
- PQ
Pietro Quaglino
Dermatologic Clinic, Department of Medical Sciences, University of Turin, Italy
- EK
Erika Kis
Department of Dermatology and Allergology, University of Szeged, Hungary
- MM
Matteo Mascherini
Department of Surgical Sciences, Polyclinic Hospital San Martino, Italy
- BB
Brian Bisase
Clinic for Head and Neck Cancer, Queen Victoria Hospital National Health Service (NHS) Foundation Trust, United Kingdom
- GP
Giancarlo Pecorari
Department of Surgical Sciences, Otolaryngology Clinic, University of Turin, Italy
- FB
Falk Bechara
Department of Dermatologic Surgery, Ruhr-University Bochum, Germany
- PM
Paolo Matteucci
Dept Plastic Surgery, Hull University Teaching Hospitals National Health Service (NHS) Trust, United Kingdom
- JO
Joy Odili
Department of Plastic Surgery, St. Georges University Hospitals National Health Service (NHS) Trust, United Kingdom
- FR
Francesco Russano
Melanoma and Sarcoma Surgical Oncology Unit, Veneto Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Italy
- AO
Antonio Orlando
Southmead Hospital, North Bristol National Health Service (NHS) Trust, Department of Plastic and Reconstructive Surgery, United Kingdom
- RP
Rowan Pritchard-Jones
Plastic Reconstructive Surgery, University of Liverpool, St. Helens & Knowsley Teaching Hospitals National Health Service (NHS) Trust, United Kingdom
- GM
Graeme Moir
Department of Cutaneous Medicine and Surgery, The Royal London Hospital & Queen Mary University of London (QMUL), Bart’s Health National Health Service (NHS) Trust, United Kingdom
- DM
David Mowatt
Department of Surgery, Christie Hospital, United Kingdom
- BS
Barbara Silvestri
Oncology and Haematology Unit, Azienda Unità Sanitaria Locale Socio Sanitaria (AULSS) 3 Serenissima-Mirano, Italy
- VS
Veronica Seccia
Otorhinolaryngology Audiology and Phoniatric Unit, University Hospital of Pisa, Italy
- WS
Werner Saxinger
Department of Dermatology, Klinikum Wels-Grieskirchen, Austria
- FD
Francesca de Terlizzi
Department of Dermatology, Klinikum Wels-Grieskirchen, Austria
- GS
Gregor Sersa
Department of Experimental Oncology, Institute of Oncology Ljubljana, Slovenia
11 Authors
- KH
Kevin Hollevoet
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Belgium
- DT
Debby Thomas
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Belgium
- GC
Griet Compernolle
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Belgium
- GV
Giles Vermeire
Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Belgium
- ED
Elien De Smidt
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Belgium
- SD
Stéphanie De Vleeschauwer
Laboratory Animal Center, KU Leuven – University of Leuven, Belgium
- TR
Trevor R. F. Smith
Inovio Pharmaceuticals, United States
- PD
Paul D. Fisher
Inovio Pharmaceuticals, United States
- MD
Maarten Dewilde
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Belgium
- NG
Nick Geukens
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Belgium
- PD
Paul Declerck
PharmAbs, The KU Leuven Antibody Center – University of Leuven, Belgium
3,255 views
9 citations
4 Authors
- VN
Vitalij Novickij
Faculty of Electronics, Vilnius Gediminas Technical University (Vilnius TECH), Lithuania
- NR
Nina Rembiałkowska
Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Poland
- WS
Wojciech Szlasa
Faculty of Medicine, Wroclaw Medical University, Poland
- JK
Julita Kulbacka
Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Poland

